Markets / Stocks

Kindred Biosciences Reports “Significantly Higher” Resolution Rates

Kindred Biosciences (KIN) reported early Wednesday positive results from its pilot field effectiveness study of KIND-014 for the treatment of gastric ulcers in horses, with statistically significantly higher gastric ulcer resolution rates in all KIND-014 groups versus the placebo group.

This study was a randomized, single-blind, placebo-controlled, dose-ranging study that enrolled 53 horses (40 horses in three KIND-014 groups with different doses and dosing schedules, 13 horses in the placebo group).

The company said it will be advancing KIND-014 into the next phase of development.